Skip to main content

Advertisement

Table 1 Characteristics of patients

From: Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists

  Group I Group II Group III Group IV
n 37 31 21 24
Age (median, IQR) 43 (31–59) 52 (42–56) 65 (37–72) 60 (50–72)
Gender (male/female) 19/18 13/18 11/10 14/10
IMID* (RA/SA/CD) 13/12/12 16/13/2 0 0
TNF antagonists*     
RA (Ifx/Ada/Eta) 11 (0/1/10) 12 (3/2/7) 0 0
SA (Ifx/Ada/Eta) 9 (2/1/6) 13 (8/1/4)   
CD (Ifx/Ada/Eta) 11 (11/0/0) 0 (0/0/0)   
Previous anti-TB treatment 0 2 0 20
Associated immunosuppressors (MTX/AZA/CT) 17/6/18 14/1/11 0 0
TST (≥10 mm) 0/37 31/31 0/21 24/24
  1. *A few patients were studied at inclusion but not at week 14. Ada, adalimumab; AZA, azathioprine; CD, Crohn's disease; CT, corticosteroids (≤10 mg/day); Eta, etanercept; Ifx, infliximab; IMID, immune-mediated inflammatory disease; IQR, interquartile range; MTX, methotrexate; RA, rheumatoid arthritis; SA, spondylarthropathy; TB, tuberculosis; TNF, tumour necrosis factor; TST, tuberculin skin test.